Nanoparticles as novel drug delivery systems for cancer treatment: current status and future perspectives

Liew, Kai Bin and Phang, Hiu Ching and Tan, Vinie Ying Xuan and Kee, Phei Er and Ming, Long Chiau and Vijayaraj Kumar, Palanirajan and Lee, Siew-Keah and Helal Uddin, A.B.M. and Gilhotra, Ritu M. and Ramanunny, Arya Kadukkattil (2025) Nanoparticles as novel drug delivery systems for cancer treatment: current status and future perspectives. Current Pharmaceutical Design, 31 (39). pp. 3117-3127. ISSN 1381-6128 E-ISSN 1873-4286

	PDF (Review) - Published Version Restricted to Repository staff only Download (4MB) | Request a copy
Preview	PDF (Scopus) - Supplemental Material Download (204kB) | Preview
Preview	PDF (WOS) - Supplemental Material Download (302kB) | Preview

Abstract

Cancer continues to pose a significant global health challenge, demanding innovative therapeutic approaches to overcome the limitations of conventional treatments like chemotherapy and radiotherapy. Nanoparticles (NPs) have emerged as promising tools for cancer therapy due to their unique physicochemical properties that enable targeted drug delivery, reduced systemic toxicity, and enhanced therapeutic efficacy. This comprehensive review delves into the mechanisms of NP-based drug delivery, highlighting both passive and active targeting strategies. It categorizes and discusses diverse NP types, including polymeric, lipid-based, and metallic nanoparticles, emphasizing their applications in enhancing the bioavailability and specificity of anticancer agents. This review also explores the integration of advanced technologies, such as theranostics and artificial intelligence, to optimize NP design and functionality for personalized medicine. However, challenges remain, including issues related to toxicity, drug resistance, and manufacturing scalability. Addressing these barriers re- quires interdisciplinary research focused on developing stimuli-responsive NPs, improving biocompatibility, and incorporating multimodal therapeutic platforms. Although substantial progress has been made, this review is limited by the paucity of clinical trials validating NP efficacy and safety in diverse patient populations. Fu- ture endeavors should prioritize translational research to bridge the gap between preclinical innovations and clinical applications, ensuring that these transformative technologies benefit a broader spectrum of cancer pa- tients. The review underscores the immense potential of NPs in redefining cancer treatment while advocating for sustained research to address existing limitations and unlock their full therapeutic promise.

Item Type:	Article (Review)
Additional Information:	4478/123745
Uncontrolled Keywords:	Nanoparticles, cancer treatment, anti-cancer, drug delivery, targeted therapy, radiotherapy, chemotherapy agents
Subjects:	Q Science > QD Chemistry R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica > RS192 Materia Medica-Pharmaceutical Technology R Medicine > RS Pharmacy and materia medica > RS403 Materia Medica-Pharmaceutical Chemistry
Kulliyyahs/Centres/Divisions/Institutes (Can select more than one option. Press CONTROL button):	Kulliyyah of Pharmacy > Department of Pharmaceutical Chemistry Kulliyyah of Pharmacy
Depositing User:	Dr. A. B. M. Helal Uddin
Date Deposited:	04 Nov 2025 11:19
Last Modified:	04 Nov 2025 11:21
URI:	http://irep.iium.edu.my/id/eprint/123745

Actions (login required)

View Item